14 Biotech Stocks with High Potential

Page 6 of 13

8. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Analyst Upside: 82.93%

Number of Hedge Fund Holders: 40

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks with high potential. On September 18, Needham analyst Gil Blum upgraded the rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) to a Buy, setting a price target of $14.00.

Similarly, Morgan Stanley analyst Maxwell Skor also maintained a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) on September 17, setting a $12.00 price target.

The analyst consensus rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a Strong Buy, and the stock’s median price target of $8.41 implies an upside of 78.25% from current levels.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotech company that discovers, develops, and delivers medicines to treat metabolic diseases.

Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Page 6 of 13